Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,0949€
Last updated
25/10/2025 - 19:47
+2,04%
€7.6m
Total sales in 2024
+40
Commercial opportunities following CellTolerance launch
+48%
PPU growth in 2024 vs.
2022
excluding exchange rates
Events and Presentations
Financial Results
Governance
Corporate Presentation October 2025
No results found.
Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates
No results found.
MKT – Webinar – October 6, 2025 (French only)
No results found.
Voting Rights Information – September 2025
No results found.
2025 Half-Year Financial Report (free translation)
No results found.
News
Mauna Kea Technologies Announces It Has Secured Over €5M in Firm Subscription Commitments as Required for Its Capital Increase
Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates
Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan
No results found.
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 79,439,997
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISIN : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
GILBERT DUPONT
Guillaume Cuvillier
EUROLAND CORPORATE
EUROLAND CORPORATE
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France